Key result
Detectable hs-cTnT linked to ~613% higher MACE risk in rheumatoid arthritis.
Why the study?
Patients with rheumatoid arthritis have an excess risk of cardiovascular disease, while detectable high-sensitivity cardiac troponin is associated with major adverse cardiovascular events and mortality in the general population.
Is high-sensitivity cardiac troponin T associated with major adverse cardiovascular events in patients with rheumatoid arthritis?
Cohort (n=331)
No
Is high-sensitivity cardiac troponin T associated with major adverse cardiovascular events in patients with rheumatoid arthritis?
Hazard Ratio: 7.13 (95% CI 2.29–22.1)
p-value: p=<0.001
Patients with rheumatoid arthritis (RA) have a 1.5-times excess risk of cardiovascular (CV) disease compared to the general population, attributed to chronic inflammation.1,2 In the general population, detectable levels of high-sensitivity cardiac troponin (hs-cTn) are associated with higher risk of major adverse CV events (MACE) and all-cause mortality.3
No takes yet. Share an insight, caveat, or question.
Weber et al. (2024) conducted a cohort in Rheumatoid arthritis (n=331). Detectable high-sensitivity cardiac troponin T (hs-cTnT) vs. Undetectable hs-cTnT was evaluated on Major adverse cardiovascular events (MACE: acute coronary syndrome, stroke, and CV death) (HR 7.13, 95% CI 2.29-22.10, p=<0.001). In patients with rheumatoid arthritis, detectable high-sensitivity cardiac troponin T was associated with a significantly increased risk of future major adverse cardiovascular events (HR 7.13).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: